A GFP-Transfected HFWT Cell Line, GHINK-1, as a Novel Target for Non-RI Activated Natural Killer Cytotoxicity Assay

Adoptive NK-cell transfer as a potential treatment paradigm for Wilms tumor: A preclinical study

BACKGROUND

Natural killer (NK) cell therapy has been shown to be effective in the treatment of some cancers. However, the effects of this adoptive immunotherapy have not been investigated for Wilms tumor (WT). In this study, the effects of adoptive NK-cell transfer on a patient-derived xenograft (PDX) model of anaplastic WT were evaluated, and the impacts of cell source and ex vivo activation strategy on the therapeutic efficacy of NK-cell product were appraised.

METHODS

NK cells were isolated from human peripheral blood mononuclear cells (NK_PB ) and human cord blood (NK_CB ), and were expanded and activated using a cytokine cocktail. Another group of NK cells (NK_ET ) was produced through activation with the exosomes extracted from previously challenged NK_PB cells with WT. PDX-bearing mice were treated with clinically relevant doses of NK_PB , NK_CB , NK_ET , standard chemotherapy, and placebo (phosphate-buffered saline).

RESULTS

PDX models treated with NK_CB showed a better survival rate, though the difference among the study groups was not significant. Compared with the placebo control group, NK_CB significantly improved the histopathologic response, NK_PB significantly inhibited the proliferation of neoplastic cells, and NK_ET led to a significant decrease in the metastasis score (all p-values <.05). Standard chemotherapy provided the greatest tumor growth inhibition and the lowest mitotic count, though it did not show any significant advantage over NK-cell therapies in any of the outcome parameters in two-by-two comparisons.

CONCLUSIONS

This study spotlights the efficacy of adoptive NK-cell transfer as a potential treatment candidate for high-risk WT.

Implementation of the EGFP-K562 flow cytometric NK test: Determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding

BACKGROUND

Natural Killer (NK) cells are key actors of innate immunity that supervise the organism's cells, and fight against viral infections and cancer development through their cytotoxic activity. This cytotoxic activity is modulated by cytokines and hormones and could be influenced by physiological or pathological conditions. New techniques for measuring NK cytotoxic activity by flow-cytometry have recently been developed, and they correlated strongly with the standard chromium ((51)Cr) release assay. Our aim was to implement a previously published enhanced green fluorescent protein (EGFP)-K562 flow cytometric method and use it to evaluate NK cytotoxic activity under different nutritional conditions.

METHODS

NK effector cells were isolated from peripheral blood mononuclear cells, and a K562 cell line stably transfected by EGFP was used as target cells. Different analytical parameters, including cell ratios and incubation times, were studied to improve the EGFP-K562 flow cytometric NK test conditions.

RESULTS

The optimized test was then used to determine the effect of fasting and refeeding on NK cell numbers and activity in a physiological situation. NK cytotoxic activity in fasted conditions (30.4 +/- 4.4%) increased by a factor 1.7 +/- 0.2 (P = 0.0025) in nourished conditions (45.0 +/- 4.6%) in healthy elderly people.

CONCLUSION

Therefore, this method provides a reliable, reproducible and rapid test for analyzing NK cytotoxicity under various conditions.

Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice

NK cells are large granular lymphocytes that represent a critical component of the innate immunity. Investigations of human NK cell function are largely based on in vitro assays because of the lack of suitable animal models. Here we have established conditions leading to the development of human NK cells in NOD/SCID (severe combined immunodeficiency) mice receiving grafts of cord blood mononuclear cells (CBMC), and GFP-transduced HFWT inducing NK cells (GHINK-1), which have been shown to support the selective expansion of NK cells from human PBMC and CBMC in vitro. Significant numbers of CD56dimCD16+ cytotoxic and CD56-CD16+ immature NK cells appeared in peripheral blood (PB), peritoneal cavity, spleen, bone marrow and liver of the mice. The newly generated NK cells did not express activation markers such as CD25, CD69 and NKp44, the expression of which was augmented by IL-2 in vitro. The NOD/SCID mice engrafted with human NK cells exhibited antitumor activity against K562 erythroleukemia in vitro and in vivo. Thus, we succeeded in developing a CD56dimCD16+ cytotoxic NK cell populations in NOD/SCID mice closely resembling the main NK fraction in human PB and CD56-CD16+ immature NK cells. Our model provides not only information about the development and dynamics of physiological human NK cells but also an important pre-clinical system for immunotherapeutic strategies.